Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Legend Biotech Corporation

Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech to Host Investor Conference Call on Third-Quarter Results
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Announces Participation in Upcoming Investor Conference
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Corporation Announces Pricing of Public Offering
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Corporation Announces Proposed Public Offering
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Announces Appointment of Global Head of Research and Early Development
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Corporation Announces Pricing of Public Offering
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Corporation Announces Proposed Public Offering
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech to Present at the Jefferies Virtual Healthcare Conference
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Reports First Quarter 2021 Financial Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
Tickers LEGN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.